One of the elements lacking in the personalized medicine discussion today is the perspective of leading clinicians, informaticists and academics working in the field. To remedy the gap, I've asked a series of leaders in the industry to offer up their views.
Genomic sequencing specialist GenapSys picked up $37 million in Series B financing to help develop and commercialize its diagnostic system for genetic diseases, cancer and microbes.
Illumina has partnered with Hamilton Robotics to develop automated sample preparation for the company's next-generation sequencing platforms.
After months of hints and allegations, Thermo Fisher has come out on top in the scrum to acquire Life Technologies, signing a deal to buy the sequencing giant for $13.6 billion.
GE Healthcare has been steadily building up its diagnostics offerings over the past three years, and now the company is launching a sequencing assay targeting solid tumors in clinical trials.
The hot and cold rumors over a potential Life Technologies sale have swung back toward the former, as Bloomberg 's sources say a team of private equity outfits are exploring an offer for the sequencing giant.
Delisted and largely dumped by investors after a pair of restructurings failed to cure what ailed it, Cambridge, MA-based Helicos BioSciences ($HLCS) has stepped into bankruptcy court seeking Chapter 11 protection for the genomic sequencing company.
Personalized medicine has the potential to revolutionize biotech and pharma, but only if stakeholders work together, Levin said.
Life Technologies is lining up its pieces to get more of the genetic sequencing market with a manufacturing plant expansion in Scotland.
This week Pacific Biosciences--the biotech superstar that has raised hundreds of millions in venture capital and launched an IPO--started shipping its PacBio RS system. According to a release, the